Extended Data Fig. 1: Experimental schemas, efficacy and pharmacodynamic data for CT26 and EO771 studies.
a, Experimental schemas. Tumor growth and PD/multi-omics analysis for CT26 and EO771 studies (left); delayed FTY720 treatment in CT26 model (right). b, c, Mouse EO771 orthotopic tumor model. b, FTY720 treatment impairs efficacy of anti-PD-1 and anti-TIGIT treatment in EO771 tumor model. C57BL/6 mice inoculated in mammary fat pad with EO771 tumor cells and treated with isotype control, anti-PD-L1, anti-TIGIT, or the combination of anti-PD-L1 and anti-TIGIT antibodies, with or without FTY720. Tumor growth was monitored and grouped analysis and growth curves for each individual animal are shown (n = 10 animals per group). Data shown are representative of two independent experiments. c, Total numbers of CD8+ T cells, CD4+ T cells or Tregs in dLN (top panels) or tumor (bottom panels) of CT26 tumor-bearing mice treated with isotype control, anti-PD-L1, anti-TIGIT or the combination, with or without FTY720. n = 5 animals per sample and treatment group, mean ± s.d. are represented by bars and whiskers. Data are representative of three independent experiments.
